Drug Profile


Alternative Names: 60P 003; Etaquine; SB-252263; SB-252263-AAB; SB-252263-AX; Tafenoquine succinate; UNII-DL5J0B8VSS; WR 238605; WR 238605 succinate

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Walter Reed Army Institute of Research
  • Developer 60 Degrees Pharmaceuticals; GlaxoSmithKline; Medicines for Malaria Venture; Walter Reed Army Institute of Research
  • Class Aminoquinolines; Antimalarials; Antiprotozoals; Small molecules
  • Mechanism of Action Apoptosis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malaria
  • Discontinued Babesiosis; Pneumocystis pneumonia

Most Recent Events

  • 13 Jun 2017 Efficacy and safety data from the phase III DETECTIVE and GATHER trial in Malaria released by GlaxoSmithKline
  • 12 Jun 2017 GlaxoSmithKline plans to file regulatory application for Malaria later in 2017
  • 17 May 2017 Pharmacodynamics and adverse events data from a preclinical study in Malaria released by 60 Degrees Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top